GlassScriptPhysician profile
Anitha D Yadav
NPI 1760691158
$3,745.12
in general payments reported to CMS, 2019-2025
22 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $181 · 2021: $466 · 2022: $425 · 2023: $380 · 2024: $770 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.57 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,795.03 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $352.64 | 2021-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $205.04 | 2024-2025 | Voquezna |
| Pfizer INC. | $186.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.51 | 2019-2025 | Entyvio, Eohilia |
| Ipsen Biopharmaceuticals, INC | $137.02 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $125.74 | 2023-2025 | Omvoh |
| Genzyme Corporation | $118.20 | 2025 | |
| Madrigal Pharmaceuticals | $81.05 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $79.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.78 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Intercept Pharmaceuticals, INC. | $68.73 | 2019-2025 | |
| Ardelyx, INC. | $66.10 | 2025 | Ibsrela |
| Shionogi INC | $53.50 | 2019 | |
| Abbott Laboratories | $48.05 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $46.56 | 2024-2025 | Vegzelma |
| Braintree Laboratories, INC. | $32.01 | 2023-2024 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $31.40 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $16.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.54 | 2023 | Cimzia |
| Evoke Pharma, INC. | $15.49 | 2024 | |
| Medtronic, INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.